MIM
MRNA icon

MetLife Investment Management’s Moderna MRNA Stock Holding History

MetLife Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.67M Sell
80,961
-466
-0.6% -$24.1K 0.03% 595
2026
Q1 		$4.14M Sell
81,427
-2,097
-3% -$97.8K 0.02% 702
2025
Q4 		$2.46M Sell
83,524
-2,531
-3% -$68.8K 0.01% 976
2025
Q3 		$2.22M Sell
86,055
-899
-1% -$25.1K 0.01% 1035
2025
Q2 		$2.4M Sell
86,954
-719
-0.8% -$18.9K 0.01% 922
2025
Q1 		$2.49M Sell
87,673
-1,684
-2% -$59.8K 0.01% 939
2024
Q4 		$3.72M Buy
89,357
+1,667
+2% +$79.7K 0.02% 728
2024
Q3 		$5.86M Sell
87,690
-1,056
-1% -$97K 0.03% 445
2024
Q2 		$10.5M Buy
88,746
+11,066
+14% +$1.4M 0.06% 230
2024
Q1 		$8.28M Sell
77,680
-2,857
-4% -$288K 0.06% 283
2023
Q4 		$8.01M Sell
80,537
-1,387
-2% -$117K 0.06% 277
2023
Q3 		$8.46M Sell
81,924
-1,452
-2% -$162K 0.07% 244
2023
Q2 		$10.1M Sell
83,376
-2,714
-3% -$362K 0.07% 221
2023
Q1 		$13.2M Sell
86,090
-1,023
-1% -$169K 0.1% 160
2022
Q4 		$15.6M Sell
87,113
-3,063
-3% -$501K 0.12% 135
2022
Q3 		$10.7M Sell
90,176
-3,843
-4% -$583K 0.09% 180
2022
Q2 		$13.4M Sell
94,019
-16,820
-15% -$2.4M 0.1% 152
2022
Q1 		$19.1M Buy
110,839
+32,903
+42% +$5.54M 0.12% 130
2021
Q4 		$19.8M Sell
77,936
-1,380
-2% -$403K 0.16% 103
2021
Q3 		$30.5M Buy
+79,316
New +$29.3M 0.27% 64
2019
Q2 		– Sell
-108
Closed -$2.47K – 2540
2019
Q1 		$2.47K Buy
+108
New +$2K ﹤0.01% 2561

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

MetLife Investment Management's MRNA Position: Q2 2026 in Review

MetLife Investment Management reduced its Moderna (MRNA) stake by 0.57% in Q2 2026, selling an estimated $24.1K and leaving 80,961 shares worth $5.67M. The position accounts for 0.03% of the portfolio, ranked #595.

MetLife Investment Management first reported a position in MRNA in Q1 2019 and has held it in 21 quarters since. The position peaked at $30.5M in Q3 2021. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • MetLife Investment Management held 80,961 shares of Moderna worth $5.67M as of Q2 2026.
  • MetLife Investment Management sold 466 Moderna shares in Q2 2026, an estimated $24.1K.
  • Moderna made up 0.03% of MetLife Investment Management's portfolio in Q2 2026, its #595 holding.
  • MetLife Investment Management first reported a position in Moderna in Q1 2019 and has held it in 21 quarters since.
  • MetLife Investment Management's Moderna position peaked at $30.5M in Q3 2021.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.